Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
SelectI am a U.S. Healthcare ProfessionalYes, I am a U.S. Healthcare Professional
I am a U.S. Patient / CaregiverNo, go back to the patient portal
SelectI am a U.S. Patient / CaregiverNo, go back to the patient portal
Non-US residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Poster
Liu G, Iadeluca L, Reisman A, Blackhall F, Mazieres J September 12, 2022 ESMO 2022 Lung Cancer

Health-Related Quality of Life in Patients With ALK+ Non-Small Cell Lung Cancer in the Phase 3 CROWN Study

View Presentation View Abstract Plain Language Summary
Poster
Bearz A, Felip E, Mazieres J, de Marinis F, Bauer T, Polli A, Messina R, Thurm H, Thomaidou D, Mok T, Solomon BJ September 12, 2022 ESMO 2022 Lung Cancer

Long-Term Intracranial Safety and Efficacy Analyses From the Phase 3 CROWN Study

View Presentation View Abstract Plain Language Summary
Poster
Felip E, Martini J-F, Mazieres J, Kim D-W, Shepard D, Polli A, Liu G, de Marinis F, Toffalorio F, Goto Y, Solomon BJ September 12, 2022 ESMO 2022 Lung Cancer

Resistance Mechanisms to Lorlatinib or Crizotinib in Treatment-Naive Patients With ALK+ Advanced Non-Small Cell Lung Cancer

View Presentation View Abstract Plain Language Summary
Poster
Zhou Q, Kim HR, Soo R, Chiu C-H, Hayashi H, Kim S-W, Teraoka S,  Kim D-W, Zhan H, Zhao H, Li H, Mok T, Wu Y-L September 12, 2022 ESMO 2022 Lung Cancer

Updated Analyses From the CROWN Study of First-Line Lorlatinib vs Crizotinib in Asian Patients With ALK-Positive Non-Small Cell Lung Cancer

View Presentation View Abstract Plain Language Summary
Poster
Bailey H, Burlison H, Chandrasekar S, Wong CH, Forshaw C, Duncan K April 1, 2023 ELCC 2023 Lung Cancer

Real-World Disease Characteristics and Treatment Patterns in Patients With Advanced Non-Small Cell Lung Cancer and EGFR in Brazil and Taiwan

View Presentation
Poster
Riely GJ, Smit EF, Ahn M-J, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Otterson GA, Dagogo-Jack I, Alcasid A, Usari T, Wilner K, Pathan N, Johnson BE June 4, 2023 ASCO 2023 Lung Cancer

Efficacy and Safety of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant (BRAFV600E) Metastatic Non-Small Cell Lung Cancer (NSCLC) From the Phase 2 PHAROS Study

View Presentation View Abstract Plain Language Summary
Poster
Bauer TM, Felip E, Mok TSK, Wu Y-L, Liu G, Goto Y, Kim D-W, Paolini J, Polli A, Solomon BJ June 4, 2023 ASCO 2023 Lung Cancer

Management of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Who Received Brain Radiotherapy on Study in the Phase 3 CROWN Trial

View Presentation View Abstract Plain Language Summary